Erlotinib - Drug Monograph | DrugInfoSys ODIS

Primary Characteristics

It belongs to Quinazolinamine.

It belongs to Epidermal Growth Factor Receptor pharmacological group on the basis of mechanism of action.

Molecular Weight: 429.9 · pK_a: 5.42 · Solubility in Water: slightlysoluble · Solubility in Alcohol: slightly soluble · Non-proprietary name: Erlotinib · pH: 2.

Pharmacokinetics

Absorption: Erlotinib has an oral bioavailability is 60%.

Distribution: Erlotinib has a plasma protein binding is 93%.

Elimination: it is metabolised via hepatic, plasma half-life is 36.2, renal excretion is <9%.

Indications

Erlotinib is primarily indicated in conditions like Metastatic lung cancer, Metastatic pancreatic cancer, Non small cell lung cancer.

Contraindications

Erlotinib is contraindicated in conditions like Cough, Dyspepsia, Fever, Pulmonary disease, fever, Gastrointestinal perforation.

Dosage

Erlotinib's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
100 mg	100 mg	Every 24h	oral	For non-small cell PANCREATIC cancer, should be taken at least one hour before or two hours after the ingestion of food.
150 mg	150 mg	Every 24h	PO	For non-small cell LUNG cancer, should be taken at least one hour before or two hours after the ingestion of food.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

16 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Erlotinib in overdosage may give rise to further complications which include Skin rashes .

Erlotinib produces potentially life-threatening effects which include GI perforation, Interstitial lung disease. Careful monitoring is needed with proper medical management.

Erlotinib is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Anorexia , Conjunctivitis, Cough , Diarrhea, Dry skin, dyspepsia, Dyspnea, Fatigue, GI bleeding, GI disturbance, Alopecia, Infection, Keratoconjunctivitis sicca, Nausea, Pruritis, Pruritus , Rashes , Stomatitis, Vomiting .

Warnings / Precautions

Treatment should continue until disease progression or unacceptable toxicity occurs. In patients who develop an acute onset of new or progressive pulmonary symptoms, such as dyspnea, cough or fever, treatment with Erlotinib should be interrupted pending diagnostic evaluation. If Interstitial Lung Disease (ILD) is diagnosed, Erlotinib should be discontinued and appropriate treatment instituted as necessary. Interrupt or discontinue Erlotinib in patients with dehydration who are at risk for renal failure, in patients with severe bullous, blistering or exfoliative skin conditions, or in patients with acute /worsening ocular disorders.Avoid in pregnancy Caution is advised when Erlotinib is used with antacids, proton pump inhibitors, H2 receptor antagonist

Interference in Pathology

Erlotinib may interfere in the diagnosis of asymptomatic increase in Liver transaminase.

Available Brands

None recorded.

Storage Conditions

Erlotinib should be stored .

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs